DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kirpekar, Rashmi | ko |
dc.contributor.author | Yorgin, Peter D. | ko |
dc.contributor.author | Tune, Bruce M. | ko |
dc.contributor.author | Kim, Mi-Kyung | ko |
dc.contributor.author | Sibley, Richard K. | ko |
dc.date.accessioned | 2008-07-11T05:09:58Z | - |
dc.date.available | 2008-07-11T05:09:58Z | - |
dc.date.created | 2012-02-06 | - |
dc.date.created | 2012-02-06 | - |
dc.date.issued | 2002-06 | - |
dc.identifier.citation | AMERICAN JOURNAL OF KIDNEY DISEASES, v.39, no.6, pp.1143 - 1152 | - |
dc.identifier.issn | 0272-6386 | - |
dc.identifier.uri | http://hdl.handle.net/10203/5614 | - |
dc.description.abstract | Although pulse methylprednisolone therapy (PMT) has been used successfully in the management of children with steroid-resistant nephrotic syndrome (SRNS), the relationship between initial presenting findings and renal histological characteristics to the subsequent clinical response to PMT is unknown. A retrospective analysis was conducted in a study cohort of 42 children (30 boys, 12 girls; mean age, 7.4 +/- 4.7 years) with SRNS administered PMT between June 1976 and July 1994 at Stanford University (Stanford, CA). Four diagnostic categories were created: group I, minimal change disease with or without mesangial hypercellularity (n = 10); group II, mesangial proliferation (n = 7); group III, focal segmental glomerulosclerosis (FSGS) with or without mesangial hypercellularity (n = 10); and group IV, FSGS plus mesangial proliferation (n = 15). Primary variables analyzed were remission in response to PMT with or without alkylating agent therapy and end-stage renal disease (ESRD). Remission rates were best in group I (90%) and worst in group IV (46%). With the exception of hematuria, presenting clinical features did not correlate with outcome. Segmental sclerosis, glomerular adhesion to Bowman's capsule, epithelia[ sloughing, corona (segmental scar surrounded by visceral epithelial cells), subepithelial deposits, inflammatory cells, and percentage of interstitium, immunoglobulin M (IgM), IgG, and C3 deposition univariately correlated with ESRD in univariate analysis. In a multivariate logistic regression model, only segmental sclerosis (P = 0.008) correlated with ESRD. Histological analysis is important because it identifies features, including segmental sclerosis, that portend a poor prognosis in children with SRNS. (C) 2002 by the National Kidney Foundation, Inc. | - |
dc.description.sponsorship | supported in part by grant no. 5 T32 DK07013-13 from the National Istitute of Diabetes and Digestive and Kidney Diseases (R.K.) | en |
dc.language | English | - |
dc.language.iso | en_US | en |
dc.publisher | W B Saunders Co-Elsevier Inc | - |
dc.subject | FOCAL-SEGMENTAL GLOMERULOSCLEROSIS | - |
dc.subject | INTRAVENOUS METHYLPREDNISOLONE | - |
dc.subject | COLLAPSING GLOMERULOPATHY | - |
dc.subject | ALKYLATING-AGENTS | - |
dc.subject | PODOCYTES | - |
dc.subject | DISEASE | - |
dc.subject | PHENOTYPE | - |
dc.subject | SCLEROSIS | - |
dc.subject | FEATURES | - |
dc.subject | DAMAGE | - |
dc.title | Clinicopathologic Correlates Predict the Outcome in Children With Steroid-Resistant Idiopathic Nephrotic Syndrome Treated With Pulse Methylprednisolene Therapy | - |
dc.type | Article | - |
dc.identifier.wosid | 000176399600003 | - |
dc.identifier.scopusid | 2-s2.0-0036272277 | - |
dc.type.rims | ART | - |
dc.citation.volume | 39 | - |
dc.citation.issue | 6 | - |
dc.citation.beginningpage | 1143 | - |
dc.citation.endingpage | 1152 | - |
dc.citation.publicationname | AMERICAN JOURNAL OF KIDNEY DISEASES | - |
dc.identifier.doi | 10.1053/ajkd.2002.33382 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.contributor.localauthor | Kim, Mi-Kyung | - |
dc.contributor.nonIdAuthor | Kirpekar, Rashmi | - |
dc.contributor.nonIdAuthor | Yorgin, Peter D. | - |
dc.contributor.nonIdAuthor | Tune, Bruce M. | - |
dc.contributor.nonIdAuthor | Sibley, Richard K. | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | focal segmental glomerulosclerosis (FSGS) | - |
dc.subject.keywordAuthor | minimal change disease (MCD) | - |
dc.subject.keywordAuthor | chlorambucil | - |
dc.subject.keywordAuthor | cyclophosphamide | - |
dc.subject.keywordAuthor | proteinuria | - |
dc.subject.keywordAuthor | glomerular morphometrics | - |
dc.subject.keywordAuthor | outcome | - |
dc.subject.keywordAuthor | pathology | - |
dc.subject.keywordPlus | FOCAL-SEGMENTAL GLOMERULOSCLEROSIS | - |
dc.subject.keywordPlus | INTRAVENOUS METHYLPREDNISOLONE | - |
dc.subject.keywordPlus | COLLAPSING GLOMERULOPATHY | - |
dc.subject.keywordPlus | ALKYLATING-AGENTS | - |
dc.subject.keywordPlus | PODOCYTES | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | PHENOTYPE | - |
dc.subject.keywordPlus | SCLEROSIS | - |
dc.subject.keywordPlus | FEATURES | - |
dc.subject.keywordPlus | DAMAGE | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.